Dexmedetomidine in Erector Spinae Block in Postoperative Analgesia

Mohamed Elsayed Hassan

Status: Completed

Conditions: Postoperative Pain

Treatments: Procedure: erector spinae block with bupivacaine; Procedure: erector spinae block with bupivacaine + dexmedetomidine

Study type: Interventional

Funder types: Other

Identifiers

NCT04920669

AP2014-50103

Details and patient eligibility

About

60 female patients scheduled for breast cancer surgeries, allocated in 3 groups for erector spinae block with bupivacaine and erector spinae block with dexmedetomidine added to bupivacaine and control group. During anesthesia: total intraoperative fentanyl required will be recorded. After surgery the first time of request for analgesic will be recorded. after request of analgesia all patients will be connected to PCA device containing morphine solution, the amount of morphine consumed during the first 24 hours will be recorded.

Full description

60 female patients scheduled for breast cancer surgeries, allocated in 3 groups for erector spinae block with bupivacaine and erector spinae block with dexmedetomidine added to bupivacaine and control group. During anesthesia: total intraoperative fentanyl required will be recorded. After surgery the first time of request for analgesic will be recorded. after request of analgesia all patients will be connected to PCA device containing morphine solution, the amount of morphine consumed during the first 24 hours will be recorded. Other secondary outcomes are numerical rating scales and incidence of opioid side effects.

Enrollment: 58 patients

Sex: Female

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Provision of signed and dated informed consent form
• Stated willingness to comply with all study procedures and availability for the duration of the study
• Female, aged (18-70) years
• Belongs to American Society of Anaesthesiologists physical status class II.
• Scheduled for breast cancer surgeries.

Exclusion criteria

• Patient refusal.
• Local infection at the site of the block.
• Cardiac dysfunction (ejection fraction <45%).
• Preexisting neurological or psychiatric disease, communication difficulties, inability to use the patient-controlled analgesia (PCA) device.
• Allergy to one of the study drugs.
• Pregnancy.
• Coagulopathy (PC <60% and platelet count<100.000).

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

58 participants in 3 patient groups

erector spinae block

Experimental group

Description:

erector spinae block with 20 ml bupivacaine

Treatment:

Procedure: erector spinae block with bupivacaine

erector spinae block + dexmedetomidine

Experimental group

Description:

erector spinae block with 19 ml bupivacaine + dexmedetomidine

Treatment:

Procedure: erector spinae block with bupivacaine + dexmedetomidine

control group

No Intervention group

Description:

standard general anesthesia without any block